Publications

Drug targeting can be achieved by coupling drugs or their carriers to affinity molecules, mostly antibodies (Abs), which recognise specific protein targets. However, most proteins are not expressed in an exclusive configuration but as various isoforms. Hence, selected targeting molecules may fail to target with enough efficiency in clinical trials, which is overlooked. We illustrate this by targeting intercellular adhesion molecule 1 (ICAM-1), a cell-surface protein overexpressed in many pathologies. Most ICAM-1 targeting studies used Ab R6.5, which binds ICAM-1 domain 2 (D2). Yet, literature and our data show that D2 is frequently absent among ICAM-1 isoforms. We thus produced a battery of five new Abs (B4, B6, B11, C12 and G2) and tested their ability to recognise both full-length and -D2 ICAM-1. In solution, all Abs recognised both ICAM-1 forms (from 5.3 x 1011 to 4.2 x 1012 sum intensity/well). Coating them on nanocarriers (NCs) rendered G2 specific against -D2 ICAM-1 (4.2 x 106 NCs/well) while other Abs kept their dual recognition (from 6.4 x 106 to 2.2 x 107 NCs/well). All Abs induced NC intracellular uptake in respective cells (from 42% to 85%) and displayed good cross-species reactivity (from 4.4 x 1011 to 2.6 x 1012 sum intensity/well). These Abs represent valuable tools to target ICAM-1 and illustrate a new targeting paradigm that may improve classical strategies.

JTD Keywords: Adhesion, Antibody-targeted nanocarriers, Cross-species reactivit, Design, Domai, Endothelial delivery, Enlimomab, Icam-1, Icam-1 isoforms, Intercellular adhesion molecule 1, Nanocarriers, Nanoparticles, New recombinant antibodies, Pecam-1, Targeting and intracellular trafficking

Intercellular adhesion molecule-1 (ICAM-1) is a membrane protein whose expression is enhanced at pathological sites, supporting drug delivery using nanocarriers (NCs). Any of its five extracellular domains (D1 to D5) can be targeted, yet most NC studies have used antibody (Ab) R6.5, which targets domain D2. While this provided efficient NC targeting and intracellular transport, literature indicates the absence of D2 in about 50 % of ICAM-1 isoforms expressed in mouse models. In this study, we verified the presence of ICAM-1 isoforms lacking D2 in human cells at both mRNA and protein levels, supporting the need to test Abs targeting other ICAM-1 domains. We developed a new cell model specifically lacking ICAM-1 D2 and compared R6.5 to Abs targeting D1 (Ab 15.2), D3D4 (Ab G-5), and D5 (Ab H-4). Abs G-5 and H-4 showed best targeting results, for which they were coated on model polymeric NCs. Compared to non-specific IgG NCs, both anti-ICAM-1 formulations targeted recombinant cells expressing human ICAM-1 lacking D2 and also primary cells naturally expressing the whole ICAM-1 isoform pattern observed. Both formulations were efficiently internalized by cells and trafficked to lysosomes, as previously observed for ICAM-1-targeting systems. Furthermore, NCs coated with either one of these two Abs showed good cross-species reactivity, being amenable for future pre-clinical testing. Therefore, Abs G-5 or H-4 are good options to provide ICAM-1 targeting without missing ICAM-1 isoforms lacking D2, present in human.

JTD Keywords: Adhesion molecule-1 icam-1, Anti-icam-1 antibody, Antibody-targeted nanocarriers, Design, Different receptor epitopes, Domai, Endothelial delivery, Enlimomab, Icam-1 extracellular domains, Icam-1 isoforms, Identification, Intercellular adhesion molecule 1, Monoclonal-antibodies, Nanoparticles, Targeting and endocytosi, Transport

Transcriptomics and phosphoproteomics were carried out in the cerebral cortex of B6.Cg-Mapttm1(EGFP)Klt (tau knockout: tau-KO) and wild-type (WT) 12 month-old mice to learn about the effects of tau ablation. Compared with WT mice, tau-KO mice displayed reduced anxiety-like behavior and lower fear expression induced by aversive conditioning, whereas recognition memory remained unaltered. Cortical transcriptomic analysis revealed 69 downregulated and 105 upregulated genes in tau-KO mice, corresponding to synaptic structures, neuron cytoskeleton and transport, and extracellular matrix components. RT-qPCR validated increased mRNA levels of col6a4, gabrq, gad1, grm5, grip2, map2, rab8a, tubb3, wnt16, and an absence of map1a in tau-KO mice compared with WT mice. A few proteins were assessed with Western blotting to compare mRNA expression with corresponding protein levels. Map1a mRNA and protein levels decreased. However, β-tubulin III and GAD1 protein levels were reduced in tau-KO mice. Cortical phosphoproteomics revealed 121 hypophosphorylated and 98 hyperphosphorylated proteins in tau-KO mice. Deregulated phosphoproteins were categorized into cytoskeletal (n = 45) and membrane proteins, including proteins of the synapses and vesicles, myelin proteins, and proteins linked to membrane transport and ion channels (n = 84), proteins related to DNA and RNA metabolism (n = 36), proteins connected to the ubiquitin-proteasome system (UPS) (n = 7), proteins with kinase or phosphatase activity (n = 21), and 22 other proteins related to variegated pathways such as metabolic pathways, growth factors, or mitochondrial function or structure. The present observations reveal a complex altered brain transcriptome and phosphoproteome in tau-KO mice with only mild behavioral alterations.

JTD Keywords: computational platform, conformational-changes, cytoskeleton, disease, expression, isoforms, mechanisms, mice, phosphoproteomics, phosphorylation, synapse, tau-ko, tauopathies, transcriptomics, Animals, Cerebral cortex, Cytoskeleton, Grip2 protein, mouse, Intracellular signaling peptides and proteins, Mapt protein, mouse, Mice, Mice, knockout, Nerve tissue proteins, Neurons, Phosphoproteomics, Proteostasis, Rna, messenger, Synapse, Tau proteins, Tau-ko, Tau-protein, Transcriptomics

Heterozygous hTau mice were used for the study of tau seeding. These mice express the six human tau isoforms, with a high predominance of 3Rtau over 4Rtau. The following groups were assessed: (i) non-inoculated mice aged 9 months (n = 4); (ii) Alzheimer's Disease (AD)-inoculated mice (n = 4); (iii) Globular Glial Tauopathy (GGT)-inoculated mice (n = 4); (iv) Pick's disease (PiD)-inoculated mice (n = 4); (v) control-inoculated mice (n = 4); and (vi) inoculated with vehicle alone (n = 2). AD-inoculated mice showed AT8-immunoreactive neuronal pre-tangles, granular aggregates, and dots in the CA1 region of the hippocampus, dentate gyrus (DG), and hilus, and threads and dots in the ipsilateral corpus callosum. GGT-inoculated mice showed unique or multiple AT8-immunoreactive globular deposits in neurons, occasionally extended to the proximal dendrites. PiD-inoculated mice showed a few loose pre-tangles in the CA1 region, DG, and cerebral cortex near the injection site. Coiled bodies were formed in the corpus callosum in AD-inoculated mice, but GGT-inoculated mice lacked globular glial inclusions. Tau deposits in inoculated mice co-localized active kinases p38-P and SAPK/JNK-P, thus suggesting active phosphorylation of the host tau. Tau deposits were absent in hTau mice inoculated with control homogenates and vehicle alone. Deposits in AD-inoculated hTau mice contained 3Rtau and 4Rtau; those in GGT-inoculated mice were mainly stained with anti-4Rtau antibodies, but a small number of deposits contained 3Rtau. Deposits in PiD-inoculated mice were stained with anti-3Rtau antibodies, but rare neuronal, thread-like, and dot-like deposits showed 4Rtau immunoreactivity. These findings show that tau strains produce different patterns of active neuronal seeding, which also depend on the host tau. Unexpected 3Rtau and 4Rtau deposits after inoculation of homogenates from 4R and 3R tauopathies, respectively, suggests the regulation of exon 10 splicing of the host tau during the process of seeding, thus modulating the plasticity of the cytoskeleton.

JTD Keywords: alzheimer's disease (ad), alzheimers-disease, brain, corticobasal degeneration, globular glial tauopathy (ggt), htau, isoforms, pathological tau, pick's disease (pid), picks-disease, propagation, protein, seeding, tau splicing, tauopathy, Alzheimer disease, Alzheimer’s disease (ad), Animals, Brain, Globular glial tauopathy (ggt), Hippocampus, Htau, Humans, Mice, Mice, transgenic, Paired helical filaments, Pick disease of the brain, Pick’s disease (pid), Seeding, Tau, Tau proteins, Tau splicing, Tauopathies